ArriVent BioPharma (AVBP) Projected to Post Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP) last released its earnings results on Monday, March 3rd. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.18. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Stock Up 3.5 %

NASDAQ:AVBP opened at $20.21 on Tuesday. The company has a market cap of $687.46 million, a P/E ratio of -7.86 and a beta of 1.00. The firm’s 50 day moving average is $24.82 and its two-hundred day moving average is $26.68. ArriVent BioPharma has a fifty-two week low of $14.35 and a fifty-two week high of $36.37.

Analyst Ratings Changes

AVBP has been the topic of several research reports. B. Riley started coverage on ArriVent BioPharma in a research report on Thursday, March 20th. They issued a “buy” rating and a $37.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $39.00 price objective on shares of ArriVent BioPharma in a report on Friday, March 7th. Finally, Guggenheim started coverage on ArriVent BioPharma in a report on Monday, March 10th. They set a “buy” rating and a $45.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, ArriVent BioPharma presently has an average rating of “Buy” and a consensus target price of $39.00.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.